Utama › Kanser Ovari › California › Santa Monica
Kajian klinikal Kanser Ovari di Santa Monica, CA
15 kajian untuk Kanser Ovari sedang mencari peserta di lokasi dalam dan sekitar Santa Monica (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Mengambil pesertaFasa 2
- Saint John's Cancer Institute, Santa Monica
A Study of PHST001 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Precision NextGen Oncology & Research Center, Beverly Hills · 6 mi jauh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Mengambil pesertaFasa 1
- Research Site, Santa Monica
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Mengambil pesertaKajian pemerhatian
- UCLA Medical Center, Santa Monica
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
- Kivu Trial Site, Santa Monica
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
- UCLA Santa Monica, Santa Monica
- Beverly Hills Cancer Center, Beverly Hills · 6 mi jauh
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Mengambil pesertaFasa 1/2
- Research Site, Santa Monica
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Mengambil pesertaFasa 3
- Site 0104, Beverly Hills · 6 mi jauh
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Mengambil peserta
- Tower Cancer Research Foundation, Beverly Hills · 6 mi jauh
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Mengambil pesertaFasa 3
- Kaiser Permanente-Woodland Hills, Woodland Hills · 12 mi jauh
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Mengambil pesertaFasa 2
- University of California Los Angeles Rheumatology, Westwood, Los Angeles · 4 mi jauh
- Precision NextGen Oncology & Research Center, Beverly Hills · 6 mi jauh
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Mengambil pesertaFasa 1
- UCLA Department of Medicine - Hematology & Oncology, Santa Monica
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- UCLA David Geffen School of Medicine, Division of Hematology/Oncology, Santa Monica
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Mengambil pesertaFasa 1
- University of California, Los Angeles, Santa Monica
A Beta-only IL-2 ImmunoTherapY Study
Mengambil pesertaFasa 1/2
- Providence Saint John's Health Center, Santa Monica
Kajian Kanser Ovari di bandar lain
- Houston, TX89 kajian
- New York City, NY69 kajian
- Boston, MA61 kajian
- Los Angeles, CA50 kajian
- Nashville, TN49 kajian
- Arlington, VA46 kajian
- Philadelphia, PA44 kajian
- Columbus, OH39 kajian
- St. Louis, MO38 kajian
- Chicago, IL36 kajian
- San Antonio, TX31 kajian
- Cleveland, OH30 kajian
Kajian lain di Santa Monica
- Kanser Paru-paru Bukan Sel Kecil45 kajian
- Kanser Payudara28 kajian
- Kanser Kolorektal23 kajian
- Kanser (semua jenis)22 kajian
- Kanser Metastatik19 kajian
- Kanser Paru-paru15 kajian
- Kanser Prostat15 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher13 kajian
- Kegagalan Jantung11 kajian
- Kanser Endometrium10 kajian
- Kanser Perut9 kajian
- Kanser Pankreas9 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.